Trials Open to Enrollment

AIDS Clinical Trials: New Trials Open to Enrollment http://llwww.actis.orglactinewl.html
plasma HIV-1 -RNA following T cell activation represents the activation of latently infected
cells or an increase in cells permissive for replacing viral mutants. For more information, view
the Protocol Database record.
M~ L A Phase HI, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and
Efficacy of Adefovir Dipivoxil (bis-POM PMEA) in Prolonging Survival of HIV-Infected
Individuals With a CD4+ Cell Count of <= 100/mm3 NIAID CPCRA 039. Drug: Adefovir
dipivoxil.
The purpose of this Community Programs for Clinical Research on AIDS study is to evaluate
the safety and efficacy of adefovir dipivoxil in prolonging survival of patients with advanced
HIV disease and CD4+ cell counts of <= 100 cells/mm3. For more information, view the
Protocol Database record.
Nf L A Randomized Trial of Immediate Versus Deferred Indinavir in Addition to
Background Antiretroviral Therapy in HIV-Infected Patients With CD4+ Cell Counts
Between 200 and 500/mm3 and Plasma HIV RNA Levels >= 10,000 Copies/mL. NIAID
CPCRA 041. Drug: Indinavir sulfate.
The purpose of this Community Programs for Clinical Research on AIDS study is to evaluate
the effect of immediate versus deferred indinavir (IDV) in addition to background therapy on
disease progression or death in patients with CD4+ cell counts between 200 and 500
cells/mm3 and plasma HIV RNA levels >= 10,000 copies/mL. For more information, view the
Protocol Database record.
NM Q An Expanded Access Open Label, Compassionate Use Protocol of Remune in HIV-1
Infected Adults With CD4 Count Less Than 300 cells/ml. FDA 093. Drug: HIV-I
Immunogen.
The purpose of this Immune Response Corporation sponsored study is to provide product
through an expanded access program to HIV infected patients with CD4 counts less than 300
cells/ml. For more information, view the Protocol Database record.
M l An Expanded Access Open Label Protocol of Remune (HIV-Immunogen) in HIV-1
Infected Adults With CD4 Count 550 Cells /ml and Greater FDA 094. Drug: HIV-1
Immunogen.
The purpose of this Immune Response Corporation sponsored study is to provide an option
for therapy to WV-infected patients for which there is no comparable or satisfactory
alternative drug or therapy available. For more information, view the Protocol Database
record.
t LI An Open Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of
Viramune (Nevirapine) in Adult and Pediatric Patients with Progressive HIV Disease.
FDA 200D. Drug: Nevirapine.

The purpose of this Hoffmann - La Roche, Inc. sponsored study is to provide access to
Viramune and to evaluate the tolerance and safety of Viramune in patients with progressive,
symptomatic HIV disease who failed or are intolerant to currently approved treatment for